Contineum Therapeutics, Inc.
CTNM Nasdaq
SEC CIK 1855175
Follow Contineum Therapeutics
Weekly email: filings, results
Net income
−$18.7M
−46.2% vs same quarter last year
EPS, diluted
−$0.49
−8.9% vs same quarter last year
Operating cash flow
−$11.1M
+9.3% vs same quarter last year
Operating income
−$21M
−40.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$60M |
| FY24 | −$42.3M |
| FY23 | $22.7M |
| FY22 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$55.5M |
| FY24 | −$33.4M |
| FY23 | $18.9M |
| FY22 | - |